Paul J Chu
Overview
Explore the profile of Paul J Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saito T, Shukla N, Sato-Kaneko F, Sako Y, Hosoya T, Yao S, et al.
ACS Chem Biol
. 2022 Jan;
17(1):217-229.
PMID: 34985883
There remains an unmet need for reliable fully synthetic adjuvants that increase lasting protective immune responses from vaccines. We previously reported a high-throughput screening for small molecules that extended nuclear...
2.
Saito T, Sako Y, Sato-Kaneko F, Hosoya T, Yao S, Lao F, et al.
Front Immunol
. 2021 Oct;
12:701445.
PMID: 34650551
As viruses continue to mutate the need for rapid high titer neutralizing antibody responses has been highlighted. To meet these emerging threats, agents that enhance vaccine adjuvant activity are needed...
3.
Shukla N, Chan M, Lao F, Chu P, Belsuzarri M, Yao S, et al.
Bioorg Med Chem
. 2021 Jul;
43:116242.
PMID: 34274759
In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens...
4.
Sato-Kaneko F, Yao S, Lao F, Shpigelman J, Messer K, Pu M, et al.
Front Immunol
. 2020 Jul;
11:1207.
PMID: 32636840
The limited efficacy of seasonal influenza vaccines is usually attributed to ongoing variation in the major antigenic targets for protective antibody responses including hemagglutinin (HA) and neuraminidase (NA). Hence, vaccine...
5.
Chan M, Lao F, Chu P, Shpigelman J, Yao S, Nan J, et al.
J Med Chem
. 2019 Oct;
62(21):9521-9540.
PMID: 31603681
Agents that safely induce, enhance, or sustain multiple innate immune signaling pathways could be developed as potent vaccine adjuvants or coadjuvants. Using high-throughput screens with cell-based nuclear factor κB (NF-κB)...